Irene Kuhrer
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.
Journal: Frontiers in oncology
Published: May 30, 2023
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Journal: European surgery : ACA : Acta chirurgica Austriaca
Published: April 05, 2018
TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.
Journal: Annals of the New York Academy of Sciences
Published: February 25, 2018
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: November 25, 2014
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Journal: Anticancer research
Published: April 30, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression.
Journal: European journal of clinical investigation
Published: October 31, 2013
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Journal: The Journal of thoracic and cardiovascular surgery
Published: September 05, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026